Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A small number of patients using GLP-1 weight loss medications have experienced vision loss, although researchers have not ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Boone Health is closing its bariatric clinic in Columbia because of lagging demand. "We're working to expand the high-demand ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...